HOME >> MEDICINE >> NEWS
12-month study demonstrated tolerability and efficacy of Daytrana

SAN DIEGO MAY 23, 2007 Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced that DAYTRANATM (methylphenidate transdermal system), the first and only non-oral medication approved for treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6 to 12 years, provided significant improvement in symptom control and tolerability, according to results of a 12-month open-label study presented at the American Psychiatric Association (APA) annual meeting in San Diego.

"We documented that children with ADHD experienced effective ADHD treatment with use of DAYTRANA for 12 months, sustaining the improvements in their ability to maintain focus and concentration," said investigator Oscar Bukstein, M.D., M.P.H ,Associate Professor of Psychiatry, University of Pittsburgh School of Medicine. "More importantly, Daytrana maintained a favorable safety profile, meeting the study's primary endpoint, and demonstrating an incidence of adverse events that is consistent with previous trials and other stimulants in this class."

Shire's DAYTRANA is the first and only patch medication approved by the U.S. Food and Drug Administration (FDA) to treat the symptoms of ADHD in children aged 6 to 12 years. DAYTRANA is available in four dosage strengths 10 mg, 15 mg, 20 mg and 30 mg all designed for once-daily use. When worn for the recommended nine hours, efficacy has been demonstrated from the first time point measured (two hours) through the 12-hour time point. Because DAYTRANA is a patch, physicians may recommend that patients shorten the wear time if shorter duration of effect is desired or to help manage the potential for late-day side effects.

Bukstein added, "DAYTRANA's novel patch delivery system offers physicians and parents of children with ADHD a convenient, non-oral option to individualize ADHD treatment to meet their children's changing schedules."

This study was an open-label extension of four clinical trials. T
'"/>

Contact: Marion E. Glick
212-601-8273
Porter Novelli
23-May-2007


Page: 1 2 3

Related medicine news :

1. $1.5 billion needed to ensure 12-month stockpile of pediatric vaccines
2. Childhood obesity indicates greater risk of school absenteeism, Penn study reveals
3. Penn study finds pro-death proteins required to regulate healthy immune function
4. New study shows promise in reducing surgical risks associated with surgical bleeding
5. New study counts the economic cost of persistent pain in Australia
6. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA
7. Most seniors now have drug coverage, U-M study shows
8. To gain muscle and lose fat, drink milk: study
9. Wheres the beef? Not enough of it is on elders plates, muscle-metabolism study suggests
10. Even older women at high risk have little interest in being tested for HIV, study finds
11. Metabolic study in mice could lead to good cholesterol boosters

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/2/2016)... ... 2016 , ... The annual time frame to change Medicare health and prescription ... December 7th. Currently-enrolled Medicare beneficiaries who are looking to switch from their current plan ... to make changes during this period order for their new policy to go into ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet’s newest campaign, “Digestive Heath,” ... living proof that attitude and determination can combine into the most remarkable achievements. ... the holidays. This campaign will offer patients a new-found hope, by seizing the ...
(Date:12/2/2016)... ... 2016 , ... Mediaplanet is proud to announce the launch ... innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping patients and physicians ... years in the last 3 decades,” says Dr. Valentine Fuster, a world-renowned cardiologist. ...
(Date:12/2/2016)... OH (PRWEB) , ... December 02, 2016 , ... ... of veterinarian diagnostic imaging systems and the first company to offer ... With a Heart at their tradeshow booth # 941 for the American Association ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... Yisrayl Hawkins, ... delves into how this current generation fits into Bible Prophecy. Yisrayl says this generation, ... facts pointing to this conclusion, showing how the details line up exactly with Bible ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... December 2, 2016 According ... Diagnostics/IVD Market by Product (Instruments, Reagents, Software), Technology ... Oncology, Cardiology, Nephrology, Infectious Diseases) - Forecast to ... valued at USD 60.22 Billion in 2016. This ... of 5.5% during the forecast period (2016-2021) to ...
(Date:12/2/2016)... 2016  PipelineRx, a leading medication management technology ... demonstrations of its SaaS-based telepharmacy platform, PowerGridRx™ ... 2016 Midyear Clinical Meeting and Exhibition, December 5-7 ... nearly 300 hospital clients nationally, the Company is ... to dramatically improve pharmacy operations, enhance patient safety, ...
(Date:12/2/2016)... 2016 On Thursday, December 1st ... in research, development and innovation in the biopharmaceutical industry ... held in the presence of Sergey Tsyb, Vice Minister ... Federation , Natalia Sanina, First Vice Chairman of ... Head of Roszdravnadzor, National Service of Control in Healthcare, ...
Breaking Medicine Technology:
Cached News: